Document is current
Any future updates will be listed below
-
Authors
Tonna, Joseph E.
Pierce, Jan
Brintz, Benjamin J.
Bardsley, Tyler
Hatton, Nathan
Lewis, Giavonni
Phillips, John D.
Skidmore, Chloe R.
Selzman, Craig H.
-
Funding
Funding for this research was provided by:
National Center for Research Resources, National Center for Advancing Translational Sciences, National Institutes of Health (5UL1TR001067-02, 5UL1TR001067-02)
Triple I Initiative, University of Utah
BioUtah CARES Act
- License Information
-
More Information
Article History
Received: 9 June 2023
Accepted: 30 November 2023
First Online: 8 December 2023
Declarations
:
: The trial was approved under University of Utah Institutional Review Board (IRB) Approval as #132922 and was conducted under the principles of Declaration of Helsinki and in accordance with Good Clinical Practice Guidelines. All participants provided written informed consent.
: N/A.
: Dr. Tonna is supported by a career development award (K23HL141596) from the National Heart, Lung, And Blood Institute (NHLBI) of the National Institutes of Health (NIH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. None of the funding sources were involved in the design or conduct of the study, collection, management, analysis or interpretation of the data, or preparation, review or approval of the manuscript. Jan Pierce has intellectual property related to Amniotic Fluid which the University of Utah has licensed to Eliksa Therapeutics. Jan Pierce and John Phillips have advisory roles with Eliksa Therapeutics. All other authors have no conflicts of interest related to the manuscript.
